Cellipont, Xiogenix Data Show 98-103% Accuracy in Automated Cell Therapy Fill-Finish
Image
The Woodlands, Texas – September 15, 2026 -- Cellipont Bioservices and Xiogenix have published a joint white paper showing that Xiogenix's ARES X20+ automated fill-finish platform maintained formulation volume accuracy of 98.2% at small scale and 103.6% at large scale across an approximately 17-fold increase in process scale.
The paper, titled "Scaling Cell and Gene Therapy Manufacturing with Automated Formulation and Fill-Finish," details Cellipont's evaluation of the platform across small and large-scale cell therapy manufacturing workflows.